Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .
Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Target Recruit Count
- 540
- Registration Number
- NCT01956786
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong Univesity, Shanghai, Shanghai, China
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01922141
Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 132
- Registration Number
- NCT01911780
- Locations
- 🇯🇵
1348.2.021 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
🇯🇵1348.2.019 Boehringer Ingelheim Investigational Site, Kita-ku, Osaka-shi, Osaka, Japan
🇯🇵1348.2.001 Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan
Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01865188
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Target Recruit Count
- 756
- Registration Number
- NCT01848873
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 19
- Registration Number
- NCT01841593
- Locations
- 🇬🇧
St Stephen's AIDS Trust, London, United Kingdom
Bedtime Administration of Amlodipine Versus Lisinopril
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Allina Health System
- Target Recruit Count
- 100
- Registration Number
- NCT01835418
A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study
- Conditions
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT01822639
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT01806311
- Locations
- 🇰🇷
Chungnam national university hospital,clinical trial center, Daejeon, Chungcheongbul-do, Korea, Republic of
Azilsartan Circadian and Sleep Pressure
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Sogo Rinsho Médéfi Co., Ltd.
- Target Recruit Count
- 957
- Registration Number
- NCT01762501
- Locations
- 🇯🇵
Seikei-kai New Tokyo Hospital, Matsudo, Chiba, Japan
🇯🇵Hoshi General Hospital, Koriyama, Fukushima, Japan
🇯🇵Keijukai Itabashi Clinic, Koga, Ibaraki, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.